Ipratropium detailed information

Ipratropium detailed information

Clinical data
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Inhalation
ATC code	R01AX03 (WHO) R03BB01 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Protein binding	0 to 9% in vitro
Metabolism	Hepatic
Elimination half-life	2 hours
Identifiers
IUPAC name [8-methyl-8-(1-methylethyl)- 8-azoniabicyclo[3.2.1] oct-3-yl] 3-hydroxy-2-phenyl-propanoate
CAS Number	60205-81-4
PubChem CID	43232
DrugBank	APRD00537
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H30NO3
Molar mass	389.457 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Ipratropium (as ipratropium bromide, trade name Atrovent) is an anticholinergic drug administered by inhalation for the treatment of obstructive lung diseases. It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion. It is a non-selective muscarinic antagonist, and does not diffuse into the blood, which prevents systemic side effects. Ipratropium is a derivative of atropine but is a quaternary amine and therefore does not cross the blood-brain barrier, which prevents central side effects (anticholinergic syndrome).

Ipratropium is also combined with albuterol (salbutamol) (trade names Combivent and Duoneb) for the management of COPD and asthma. Ipratropium is also combined with fenoterol (trade names Duovent and Berodual N) for the management of asthma.

Side effects are as those for other anticholinergics.

Sources

• Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
• Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
• Boeringer-Ingelheim

Footnotes

de:Ipratropiumbromid